Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Tax Provisions (2019 - 2023)

Denali Therapeutics has reported Tax Provisions over the past 5 years, most recently at $30000.0 for Q4 2023.

  • Quarterly Tax Provisions rose 600.0% to $30000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $24000.0 through Dec 2023, up 104.33% year-over-year, with the annual reading at $102000.0 for FY2025, 50.0% up from the prior year.
  • Tax Provisions was $30000.0 for Q4 2023 at Denali Therapeutics, up from -$6000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $823000.0 in Q4 2020 and troughed at -$575000.0 in Q4 2021.
  • The 5-year median for Tax Provisions is $10500.0 (2022), against an average of -$7900.0.
  • Year-over-year, Tax Provisions tumbled 169.87% in 2021 and then skyrocketed 600.0% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$113000.0 in 2019, then surged by 828.32% to $823000.0 in 2020, then tumbled by 169.87% to -$575000.0 in 2021, then surged by 98.96% to -$6000.0 in 2022, then skyrocketed by 600.0% to $30000.0 in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Tax Provisions are $30000.0 (Q4 2023), -$6000.0 (Q4 2022), and $27000.0 (Q2 2022).